Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated May 26, 2026, titled "At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT (cosibelimab-ipdl)".
Press Release May 26 2026
Filed with NSE · · 5 pages · English
Release
Sun Pharmaceutical Industries Limited on 6ix
Earlier from Sun Pharmaceutical Industries
- Sun Pharmaceutical Industries, Inc. (Sun Pharma) Initiates Voluntary U.S. Nationwide Recall of DOXOrubicin Hydrochloride Liposome...
- Sun Pharma To Acquire Organon
- Press Release Apr 27 2026
- Sun Pharma signs Definitive Agreement to Acquire Organon
- Press Release Mar 27 2026
Later from Sun Pharmaceutical Industries
- At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)
- American Skin Association annual gala recognizes Sun Pharma with corporate leadership award
- Sun Pharmaceutical Industries Limited Press Release Jul 15 2026
- Sun Pharmaceutical Industries Limited Press Release Jul 24 2026
- Sun Pharmaceutical Industries Limited Press Release Jul 29 2026
Follow Sun Pharmaceutical Industries into a list and get an email when it puts out news.
Follow Sun Pharmaceutical Industries